Silicon Laboratories Inc. — Form 10-Q Summary
Period discrepancy: Request metadata identifies 2011 Q2, but the supplied filing is for the quarter ended June 30, 2012, with comparisons to the quarter ended July 2, 2011. This summary follows the filing. Financial statements are unaudited; amounts are in U.S. dollars.
Business context and reporting period
Silicon Laboratories designs analog-intensive, mixed-signal integrated circuits for communications, consumer, industrial, automotive, medical and power-management applications. It operates fablessly, relying on third parties—principally in Asia—for wafer fabrication, assembly and testing. The filing reports the second quarter and first six months of fiscal 2012.
Financial performance
| Metric | Q2 2012 | Q2 2011 | Six months 2012 | Six months 2011 |
|---|---|---|---|---|
| Revenue | $135.7 million | $126.2 million | $261.4 million | $245.8 million |
| Gross margin | $82.8 million; 61.0% | $76.2 million; 60.4% | $157.9 million; 60.4% | $148.4 million; 60.4% |
| Operating income | $16.4 million | $16.0 million | $33.1 million | $20.9 million |
| Net income | $20.5 million | $13.4 million | $34.8 million | $11.4 million |
| Diluted EPS | $0.47 | $0.29 | $0.80 | $0.25 |
| Operating cash flow | Not separately provided | Not separately provided | $41.3 million | $26.2 million |
Q2 revenue grew 7.5% year over year, while unit volumes rose 11.6% and average selling prices declined 3.8%. For the six-month period, revenue increased 6.3%, unit volumes rose 13.2% and average selling prices declined 6.1%. Management attributed revenue growth primarily to increased market share. Q2 gross margin improved 0.6 percentage points; the filing attributes the dollar increase in gross margin partly to higher sales and the absence of certain prior-year acquisition and inventory-cancellation charges.
Net income benefited materially from tax items: the company recorded a $2.7 million income tax benefit in Q2 2012, versus $3.2 million tax expense in Q2 2011. The six-month effective tax rate was 0.2%, compared with 48.9% in the prior-year period. Management cited the release of previously unrecognized tax benefits and prior-year one-time tax charges, partly offset by non-renewal of the federal R&D tax credit.
Balance sheet, liquidity and cash flows
- At June 30, 2012, cash and cash equivalents were $173.8 million and short-term investments were $138.1 million; together they totaled $311.9 million. Current assets were $474.9 million and current liabilities were $94.4 million.
- Total liabilities were $104.1 million, down from $107.1 million at December 31, 2011. The filing reports no debt payments in the first half of 2012; it does not identify a material funded-debt balance in the supplied balance sheet.
- Operating cash flow was $41.3 million in the first half. Investing activities provided $68.3 million, largely reflecting investment sales and maturities; financing activities used $30.8 million, including $36.2 million of common-stock repurchases.
- Cash and cash equivalents increased by $78.8 million to $173.8 million from year-end. Accounts receivable rose to $72.7 million from $55.4 million; DSO increased to 48 days from 39. Inventory was $36.0 million, up from $34.8 million; DOI improved to 61 days from 63.
- The company stated existing cash, cash equivalents and investments were sufficient to meet capital requirements for at least 12 months. It expected fiscal 2012 capital expenditures of approximately $10–$14 million.
Material changes, outlook and notable items
- Q2 selling, general and administrative expense increased 23.5% year over year to $32.2 million. Management cited severance costs, primarily related to the former CEO, higher legal and acquisition-related fees, and the absence of a prior-year reduction in contingent consideration. A separation agreement with the former CEO resulted in approximately $3.2 million of total expense recognized over the service period.
- Management expected Q3 fiscal 2012 revenue of $140–$145 million and diluted EPS of $0.28–$0.33. It expected R&D expense to rise in Q3 due to Ember acquisition costs and SG&A expense to decline in absolute dollars.
- On July 3, 2012, after quarter-end, the company acquired Ember Corporation for approximately $72 million plus acquired cash net of certain liabilities. Additional consideration may be payable if acquired-product revenue exceeds $27 million over the specified one-year period. The company was still evaluating purchase-price allocation.
- The company repurchased 1.1 million shares for $38.8 million in the first six months of 2012. A new program authorized up to $100 million of repurchases through January 2013.
- All $12.5 million par value of auction-rate securities had failed auctions and were not readily accessible; their reported fair value was $11.0 million. The company said it did not expect to need the funds before maturity and recorded no other-than-temporary impairment.
- MaxLinear litigation was ongoing: MaxLinear sought declarations concerning 19 Silicon Laboratories patents, and Silicon Laboratories separately alleged infringement of 20 patents and sought an injunction. The company could not predict the outcome or financial impact.
Risks and investor verification points
Key disclosed risks include semiconductor cyclicality, falling selling prices, product and customer concentration, long design-win and qualification cycles, reliance on third-party manufacturing and testing, international and Pacific Rim concentration, inventory and receivables exposure, acquisition integration, intellectual-property litigation, and potential impairment of illiquid auction-rate securities. One customer accounted for more than 10% of first-half revenue; the ten largest customers accounted for 44%. Revenue outside the United States was 88%.
- Confirm the reporting-period mismatch: the supplied filing is Q2 2012, not Q2 2011.
- Assess how much reported earnings growth reflects the unusually low tax provision and tax-benefit releases, rather than operating performance.
- Track Q3 delivery against management’s revenue and diluted-EPS guidance, including the effect of lower average selling prices and acquisition-related spending.
- Verify Ember’s final purchase accounting, integration costs and any contingent consideration, and evaluate the impact of the $72 million acquisition on liquidity.
- Monitor customer and distributor concentration, receivables/DSO, inventory, and the outcome and costs of the MaxLinear patent litigation.